arrow_back Back to App

Support for Rare Disease Drugs During COVID-19 Pandemic

This act aims to extend exclusivity periods for drugs designed to treat rare diseases, known as orphan drugs. This gives pharmaceutical companies more time to develop and bring these important medications to market, potentially accelerating access for patients suffering from rare conditions whose treatment is often neglected.
Key points
Extends market exclusivity periods for orphan drugs by 180 days, giving companies more time to recoup research costs.
Applies to drugs for which marketing applications were submitted during the COVID-19 pandemic period.
Aims to compensate for research and development delays caused by the pandemic, ensuring patients receive needed medications faster.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_8641
Sponsor: Rep. Gottheimer, Josh [D-NJ-5]
Process start date: 2022-08-02
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

Orphan Drug COVID–19 Mitigation Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_8641.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-08-02.

What are the main provisions?

Key points include:

  • Extends market exclusivity periods for orphan drugs by 180 days, giving companies more time to recoup research costs.
  • Applies to drugs for which marketing applications were submitted during the COVID-19 pandemic period.
  • Aims to compensate for research and development delays caused by the pandemic, ensuring patients receive needed medications faster.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Gottheimer, Josh [D-NJ-5].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on Energy and Commerce.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health